HPV16 Induces Formation of Virus-p62-PML Hybrid Bodies to Enable Infection.
HPV16
L2
antiviral defense
autophagy
human papillomavirus
hybrid bodies
p62
promyelocytic leukemia nuclear bodies (PML NB)
sequestosome-1
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
05 07 2022
05 07 2022
Historique:
received:
31
05
2022
revised:
24
06
2022
accepted:
29
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Human papillomaviruses (HPVs) inflict a significant burden on the human population. The clinical manifestations caused by high-risk HPV types are cancers at anogenital sites, including cervical cancer, as well as head and neck cancers. Host cell defense mechanisms such as autophagy are initiated upon HPV entry. At the same time, the virus modulates cellular antiviral processes and structures such as promyelocytic leukemia nuclear bodies (PML NBs) to enable infection. Here, we uncover the autophagy adaptor p62, also known as p62/sequestosome-1, as a novel proviral factor in infections by the high-risk HPV type 16 (HPV16). Proteomics, imaging and interaction studies of HPV16 pseudovirus-treated HeLa cells display that p62 is recruited to virus-filled endosomes, interacts with incoming capsids, and accompanies the virus to PML NBs, the sites of viral transcription and replication. Cellular depletion of p62 significantly decreased the delivery of HPV16 viral DNA to PML NBs and HPV16 infection rate. Moreover, the absence of p62 leads to an increase in the targeting of viral components to autophagic structures and enhanced degradation of the viral capsid protein L2. The proviral role of p62 and formation of virus-p62-PML hybrid bodies have also been observed in human primary keratinocytes, the HPV target cells. Together, these findings suggest the previously unrecognized virus-induced formation of p62-PML hybrid bodies as a viral mechanism to subvert the cellular antiviral defense, thus enabling viral gene expression.
Identifiants
pubmed: 35891458
pii: v14071478
doi: 10.3390/v14071478
pmc: PMC9315800
pii:
doi:
Substances chimiques
Antiviral Agents
0
Promyelocytic Leukemia Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Biochimie. 2007 Jun-Jul;89(6-7):819-30
pubmed: 17343971
FEBS J. 2015 Dec;282(24):4672-8
pubmed: 26432171
Autophagy. 2021 Mar;17(3):779-795
pubmed: 32079454
PLoS Pathog. 2012;8(4):e1002657
pubmed: 22536154
Sci Rep. 2020 Mar 24;10(1):5356
pubmed: 32210347
J Virol. 2008 Jun;82(11):5190-7
pubmed: 18367526
PLoS One. 2008 Oct 02;3(10):e3313
pubmed: 18836553
Cell Res. 2018 Apr;28(4):405-415
pubmed: 29507397
J Virol. 2019 Jul 17;93(15):
pubmed: 31092566
J Gen Virol. 1995 Nov;76 ( Pt 11):2661-7
pubmed: 7595373
Nat Rev Microbiol. 2022 Feb;20(2):95-108
pubmed: 34522050
J Gen Virol. 1994 Dec;75 ( Pt 12):3375-83
pubmed: 7996132
PLoS Pathog. 2017 May 2;13(5):e1006200
pubmed: 28463988
Mol Cell. 2009 Feb 27;33(4):517-27
pubmed: 19250912
Cell Microbiol. 2011 Jan;13(1):32-46
pubmed: 21166973
mBio. 2013 Nov 05;4(6):e00845-13
pubmed: 24194542
Autophagy. 2006 Apr-Jun;2(2):138-9
pubmed: 16874037
J Biol Chem. 2010 Feb 19;285(8):5941-53
pubmed: 20018885
Biochem Biophys Res Commun. 2013 Apr 19;433(4):385-9
pubmed: 23537650
Cell. 2009 Jun 12;137(6):1001-4
pubmed: 19524504
Proc Natl Acad Sci U S A. 2021 Aug 17;118(33):
pubmed: 34385323
Front Public Health. 2021 Jan 20;8:552028
pubmed: 33553082
Front Cell Dev Biol. 2022 Feb 14;10:793328
pubmed: 35237597
Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16
pubmed: 17928811
J Virol. 2013 Mar;87(5):2508-17
pubmed: 23255786
mBio. 2020 Aug 12;11(4):
pubmed: 32788179
J Virol. 2015 Jul;89(14):7038-52
pubmed: 25926655
Proc Natl Acad Sci U S A. 2016 May 31;113(22):6289-94
pubmed: 27190090
Curr Protoc Protein Sci. 2004 Aug;Chapter 4:Unit 4.3
pubmed: 18429269
FEBS Lett. 2007 Jan 23;581(2):175-9
pubmed: 17188686
Comp Funct Genomics. 2004;5(1):61-8
pubmed: 18629038
J Virol. 2015 Oct;89(20):10442-52
pubmed: 26246568
Pathogens. 2020 Apr 07;9(4):
pubmed: 32272661
Exp Mol Med. 2019 Dec 11;51(12):1-13
pubmed: 31827068
Virology. 2013 Mar 1;437(1):12-9
pubmed: 23290079
Front Cell Infect Microbiol. 2020 Feb 19;10:35
pubmed: 32154186
EMBO J. 2002 Sep 16;21(18):4754-62
pubmed: 12234916
Virology. 2013 Oct;445(1-2):2-10
pubmed: 23683837
Front Immunol. 2018 May 25;9:1140
pubmed: 29887866
Antimicrob Agents Chemother. 2012 Jan;56(1):75-82
pubmed: 21968369
Nat Rev Cancer. 2018 Apr;18(4):240-254
pubmed: 29497146
Virology. 2010 Oct 25;406(2):181-8
pubmed: 20684966
PLoS Pathog. 2019 Feb 25;15(2):e1007590
pubmed: 30802273
Virology. 2014 Jul;460-461:83-90
pubmed: 25010273
J Virol. 2016 Nov 14;90(23):10629-10641
pubmed: 27654294
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
Cell Microbiol. 2014 Aug;16(8):1179-200
pubmed: 24444361
Nucleus. 2015;6(4):326-38
pubmed: 26275159
Oncogene. 2018 Nov;37(48):6275-6284
pubmed: 30018400
Cell Mol Life Sci. 2021 Jan;78(2):645-660
pubmed: 32322926
Viruses. 2021 Dec 08;13(12):
pubmed: 34960729
J Virol. 2001 Oct;75(19):9201-9
pubmed: 11533183
Theranostics. 2020 Jul 11;10(20):9032-9049
pubmed: 32802177
Nat Rev Microbiol. 2016 Jun;14(6):360-73
pubmed: 27174148
Virology. 2009 Feb 20;384(2):260-5
pubmed: 19135222
Sci Adv. 2021 Jun 30;7(27):
pubmed: 34193420
J Med Virol. 2005 Jan;75(1):114-21
pubmed: 15543569
J Virol. 2016 Jun 10;90(13):5850-5854
pubmed: 27053550
PLoS Pathog. 2015 Feb 18;11(2):e1004699
pubmed: 25693203
Bio Protoc. 2017 Nov 5;7(21):
pubmed: 29170752
Autophagy. 2011 Mar;7(3):279-96
pubmed: 21189453
J Virol. 2004 Jan;78(2):751-7
pubmed: 14694107
Methods Mol Biol. 2013;1064:101-13
pubmed: 23996252
Sci Rep. 2016 Aug 31;6:32337
pubmed: 27578500
Methods Mol Biol. 2015;1318:149-59
pubmed: 26160573
Autophagy. 2011 Apr;7(4):401-11
pubmed: 21187718